High-invasiveness human lung adenocarcinoma brain metastasis cell line and application thereof
By constructing the highly invasive human lung adenocarcinoma brain metastasis cell line A549-F3, the problem of existing models being unable to accurately simulate blood-brain barrier penetration and brain tissue interaction has been solved, enabling efficient drug screening and biomarker identification, and advancing the treatment of lung adenocarcinoma brain metastases.
Patent Information
- Application Number
- CN202510928020.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-07
- Publication Date
- 2025-11-21
AI Technical Summary
Existing lung adenocarcinoma brain metastasis cell models cannot accurately simulate blood-brain barrier penetration and brain tissue microenvironment interactions, leading to inaccurate assessment of metastatic potential. Furthermore, existing models have long modeling cycles, high costs, or introduce non-natural selection biases, failing to meet the needs of scientific research and clinical practice.
A highly invasive human lung adenocarcinoma brain metastasis cell line A549-F3 was constructed using an in vivo circulation screening method. After multiple rounds of screening and expansion culture, a cell line with highly invasive and stable brain metastasis characteristics was obtained for the purpose of studying the brain metastasis mechanism of lung adenocarcinoma and drug screening.
It provides a more suitable cell model for in-depth exploration of the brain metastasis mechanism of lung adenocarcinoma, serves as an efficient drug screening platform to screen drugs that inhibit brain metastasis of lung adenocarcinoma, and explores specific biomarkers to improve diagnostic accuracy and treatment efficacy.